The exclusive license grants GCA Therapeutics the right to clinically develop and commercialize Leptin Products in China, exclusive of Hong Kong, and Taiwan.
The company said that a version of Leptin has recently been approved in the US for treating generalized lipodystrophy and in Japan for lipodystrophy.
As part of the deal, GCAT will assume all development and regulatory responsibility and associated costs for Leptin Products in China, while Neurotez will be eligible to receive gross sales milestones up to $102.5m as well as royalties on gross sales.
The exclusive license also includes certain minimum annual sales thresholds following first commercial sales in mainland China.
Neurotez president and chief executive officer Nikolaos Tezapsidis said GCAT has a demonstrated track record of successfully developing therapeutics for the large China/Asian markets, and the company is happy delighted to enter this license agreement with them for China.
"This license is the first of what we anticipate to be a series of agreements designed to allow our program to reach the large global market of patients with Alzheimer’s disease," Tezapsidis said.
GCAT chairman Mark Tang said, "We are very excited about the potential benefits of this product for Alzheimer’s disease patients, especially given the potential market size in China, where AD is becoming increasingly prevalent and remains an unmet medical need. We look forward to a productive and profitable collaboration between Neurotez and GCAT."